-+ 0.00%
-+ 0.00%
-+ 0.00%

Missed Oscar Health's 101% Gain? Here's What Investors Got Right

Simply Wall St·11/20/2026 03:14:30
Listen to the news

If Oscar Health was on your watchlist rather than in your portfolio, the return may sting. Investors who held Oscar Health over the past year are up 100.8%, including dividends. That outcome now sits alongside Q3 2025 numbers that showed rising revenue, ongoing losses and a fair value estimate built on AI-driven platforms, membership growth and a 10.4% profit margin assumption. If that AI and data advantage was the real thesis, what should have signalled it early was more than just marketing talk?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

Oscar Health is not the only name tied to this theme. Zero in on 36 healthcare AI stocks and compare how each one is priced.

The Two Oscar Health Stories Investors Had In Front Of Them

The shares cost US$14.08 at the start of the period, so any view on Oscar Health hinged on which story about its future you thought deserved more weight.

On the bullish side, the User case put Fair Value at US$45.34, or 222% above the start price. This view was built on Oscar Health using its +Oscar and AI tools to grow revenue 10.0% with profit margins reaching 10.4% over a 5-year timeframe.

The bearish November 2025 view pointed to a Fair Value of US$11.29, 20% below the start price. It focused on higher claims costs, shifting policy risk and the chance that regulatory changes and tighter data rules would blunt the hoped-for technology driven cost savings.

NYSE:OSCR 1-Year Stock Price Chart
NYSE:OSCR 1-Year Stock Price Chart

What The Results Changed For The Oscar Health Thesis

Oscar Health moved from a Q3 2025 net loss of US$137.45 million on US$2,985.984 million of revenue to Q3 2026 net income of US$167.281 million on US$5,139.298 million of revenue, with net margin shifting from a 4.6% loss to a 3.3% profit. That turn towards profitability supported the AI and platform narrative, although regulatory and claims risks in the cautious case remain untested here.

The practical takeaway is simple. When a management team emphasizes technology and efficiency, it can be useful to track the net margin line and the medical loss ratio in later filings to see whether that story is actually turning into more durable earnings.

What Oscar Health’s Price Seems To Be Saying Now

Oscar Health trades at US$26.17 today, after a 100.8% gain over the past year. The analyst consensus Narrative on Simply Wall St sees Fair Value above that level and ties the gap to how far its AI native platform, pricing discipline and membership mix can keep supporting earnings targets.

For a buyer at today’s price, the key question is whether the market fully reflects the Narrative’s view that Oscar Health can keep improving margins while managing medical costs and policy risk as it scales ACA and CHOICE membership.

"The build out of Oscar Health’s AI native, single platform architecture, which management links to a 33% improvement in operating leverage from 2024 to 2026, positions the company to keep reducing SG&A ratios and support higher net margins and earnings over time."

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all

Oscar Health And The Wider Play

Oscar Health leans hard on data, pricing and AI heavy operations. That focus raises another question for your watchlist.

If smarter underwriting and claims handling matter here, they matter elsewhere too. One large insurer is building an AI ready tech stack around exactly that problem.

It is rolling these tools through underwriting desks, call centers and distribution channels, pursuing sharper pricing and faster claims handling.

Health offerings also plug in, with clinics, teleconsulting and workplace benefits services creating more contact points with customers.

If that model gains traction, the earnings mix could shift in ways worth watching.

That argument has a Narrative and a number behind it. → See the company one Narrative values 45% above its price